NCT06137482View on ClinicalTrials.gov

A Study to See How Safe and Tolerable Different Doses of REGN13335 Are When Administered Intravenously (IV) or Subcutaneously (SC) to Healthy Adult Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

December 6, 2023

Primary Completion Date

February 11, 2025

Study Completion Date

February 11, 2025

Conditions
Healthy Volunteers
Interventions
DRUG

REGN13335

Administered intravenous (IV) or subcutaneous (SC), sequential ascending single dose

DRUG

Matching Placebo

Administered IV or SC, sequential ascending single dose

Trial Locations (1)

8011

New Zealand Clinical Research, Christchurch

All Listed Sponsors
lead

Regeneron Pharmaceuticals

INDUSTRY

NCT06137482 - A Study to See How Safe and Tolerable Different Doses of REGN13335 Are When Administered Intravenously (IV) or Subcutaneously (SC) to Healthy Adult Participants | Biotech Hunter | Biotech Hunter